UK-based drug company GlaxoSmithKline will buy Boston-based vaccine developer Affinivax for $2.1 billion, according to press releases issued by the two companies early Tuesday. GSK will also pay up to $1.2 billion more if certain milestones are reached in Affinivax’s upcoming clinical trials for a new pneumococcal …
Read more…
Source : GlaxoSmithKline Buys New Vaccine Developer Affinivax in $3.3 Billion Deal
